- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Advances and perspectives of PARP inhibitors ; volume:8 ; number:1 ; day:11 ; month:11 ; year:2019 ; pages:1-12 ; date:12.2019
Experimental hematology & oncology ; 8, Heft 1 (11.11.2019), 1-12, 12.2019
- Creator
-
Yi, Ming
Dong, Bing
Qin, Shuang
Chu, Qian
Wu, Kongming
Luo, Suxia
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40164-019-0154-9
- URN
-
urn:nbn:de:101:1-2020030821432146306555
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yi, Ming
- Dong, Bing
- Qin, Shuang
- Chu, Qian
- Wu, Kongming
- Luo, Suxia
- SpringerLink (Online service)
Other Objects (12)
Advances in using PARP inhibitors to treat cancer
PARP inhibitors
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Prostate cancer and PARP inhibitors: progress and challenges
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
PARP Inhibitors in Ovarian Cancer: A Review
PARP inhibitors: current status and implications for anticancer therapeutics
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Advances in using PARP inhibitors to treat cancer
PARP inhibitors
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Prostate cancer and PARP inhibitors: progress and challenges
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
PARP Inhibitors in Ovarian Cancer: A Review
PARP inhibitors: current status and implications for anticancer therapeutics
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
New treatment option for ovarian cancer: PARP inhibitors
Advances in using PARP inhibitors to treat cancer
PARP inhibitors
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Prostate cancer and PARP inhibitors: progress and challenges
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
PARP Inhibitors in Ovarian Cancer: A Review
PARP inhibitors: current status and implications for anticancer therapeutics
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer